The screening of Fabry disease in male patients on dialysis and not on dialysis with chronic kidney disease in Japa
Not Applicable
- Conditions
- Male CKD patients
- Registration Number
- JPRN-UMIN000040203
- Lead Sponsor
- Kurume University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 2020
Inclusion Criteria
Not provided
Exclusion Criteria
Patients refuse the study inclusion.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Fabry disease progression in male CKD patients?
How does alpha-galactosidase A deficiency contribute to chronic kidney disease in males?
What biomarkers are associated with Fabry disease in patients with varying stages of CKD?
Are there adverse events linked to Fabry disease screening in male CKD populations?
What are the comparative outcomes of Fabry disease screening in Japan versus other regions?